by Madaline Spencer | Feb 18, 2026
Ali Mohajer, PhD, Qral Group, discusses the age-stratified burden of post-allogeneic hematopoietic stem cell transplantation (post-allo-HSCT) complications in Hurler syndrome (MPS IH). MPS IH is the most severe form of mucopolysaccharidosis type I, caused by a...
by Madaline Spencer | Feb 17, 2026
Roberto Mina, MD, Associate Professor at Winship Cancer Institute of Emory University, discusses the Majestec-9 clinical trial of Tecvayli (teclistamab) in patients with multiple myeloma (MM). MM is a form of cancer due to abnormal and uncontrolled...
by Madaline Spencer | Feb 13, 2026
Tsewang Tashi, MD, Hematologist at the Huntsman Cancer Institute at the University of Utah, discusses long-term data from the PIONEER clinical trial examining the use of avapritinib in patients with indolent systemic mastocytosis (ISM). Systemic...
by Madaline Spencer | Feb 12, 2026
Robert S. Ohgami, MD, PhD, Professor of Pathology, University of Utah, and Founding Vice President and Chief Medical Director, ARUP Institute for Research and Innovation, discusses the utilization of artificial intelligence (AI) to analyze Castleman disease (CD)...
by Madaline Spencer | Feb 11, 2026
Lynette Chee, PhD, Hematologist at The Royal Melbourne Hospital/ Peter MacCallum Cancer Centre, discusses elritercept’s effect on transfusion independence (TI) in patients with myelodysplastic syndromes (MDS). MDS are a group of blood disorders...
